Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STP 707

Next Previous
Drug Profile

STP 707

Alternative Names: STP-707

Latest Information Update: 02 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sirnaomics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Hepatoprotectants; Immunotherapies; Small interfering RNA
  • Mechanism of Action Cyclooxygenase 2 expression inhibitors; RNA interference; Transforming growth factor beta1 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Primary sclerosing cholangitis
  • No development reported Hepatic fibrosis; Pulmonary fibrosis

Most Recent Events

  • 02 Jan 2026 Phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is underway in USA (IV) (NCT05037149)
  • 22 Dec 2025 Efficacy and adverse events data from a phase I basket trial in solid tumours released by Sirnaomics
  • 22 Dec 2025 Sirnaomics completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT05037149)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top